Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Lilly and Boehringer Ingelheim to collaborate on breast cancer drug trial

Lilly and Boehringer Ingelheim to collaborate on breast cancer drug trial

14th July 2016

Lilly and Boehringer Ingelheim are to partner on the development of a new combination breast cancer therapy.

The companies will conduct a phase Ib study evaluating the safety and tolerability of abemaciclib, Lilly's CDK 4 and CDK 6 inhibitor, in combination with BI 836845, Boehringer Ingelheim's IGF-1/IGF-2 ligand neutralising antibody.

Based on the phase Ib trial results, the collaboration has the potential to expand to phase II trials. Enrolment is scheduled to begin in late 2016, with Boehringer Ingelheim to act as the sponsor of the study programme.

It is believed that using these two agents in combination could offer a more complete pathway interference and potentially prolong cell cycle arrest.

Dr Richard Gaynor, senior vice-president for product development and medical affairs for Lilly Oncology, said: "For patients living with metastatic breast cancer, the limited treatment options available make this an important area of focus for our efforts to advance the most innovative treatments."

This comes after the companies recently agreed to ally to assess the performance of their drug Jardiance as a treatment for chronic heart failure.ADNFCR-8000103-ID-801821777-ADNFCR

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.